... : Currene~ es .rod Novel Onig Devel09fl1enl CHS 3 C2()20). Increased Inhibition o l K@.t o-ffdi...ction ...
... signaling pathway ___,,,,,,, 82 ng,'ml (00 dose regimen) 5-4.04 ng/ml (80 OOH: reglfMf'I) ~ ng hrtmt. (ac ...
... > doH, regirMn) ~~~ --~- (~~~~~ 1ll \ Increased depression and anxiety 2M7 nghrfmt (e0 dose regimen) / 0 ...
... pathway .__.-,/
3 U'kg (baSM Oft a hfftthy indMdual) No eviOtnce showing PKreltted
... . s.. Amold. R. Sohacedt. A. ~=/0.~ ~-CP;J~.~xi: ::.~~-~ 01~'::~E-547 q,!Clion) in p<>Sl-pa,timd~slon ...
plus >>
Créateur:
Orr, Ashley, Hum, Julia, and Fakih, Samar
La description:
Brexanolone (ZULRESSO ™) is a novel approach to treat postpartum depression in adult women as a neuroactive steroid similar in chemical composition to the hormone allopregnanolone. It was approved for use in adult women...
Type:
Poster